Business Wire India
- in hell® Is tolerant1 And effective2 Oral calcium potassium binder for the treatment of hyperkalemia supported by 12 months of clinical data
- in hell® Fresenius Kabi’s market-leading nephrology in China with Valefor will benefit from patient access® And Venofer®
- China shows high prevalence of chronic kidney disease (CKD) and heart failure3
This press release contains multimedia. Watch the full release here: https://www.businesswire.com/news/home/20201118005914/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement for the development, registration and distribution of Veltassa® For the treatment of hyperkalemia in the People’s Miracle of China. Under the agreement, Fresenius Kabi will have exclusive rights to distribute and sell Veltas® All over China.
Stefan Schulze, CEO of Weifor Pharma Group, said, ‘We are pleased to expand VFMCRP’s collaboration with Fresenius Kabi. There is a high prevalence of CKD and heart failure in China3 And hyperkalemia is one of the most common complications associated with these two conditions. The result is a high demand for an effective, proven hyperkalemia treatment. Excellent commercial infrastructure, well-established relationships in nephrology and our current successful collaboration make Fresenius Kabi our partner of choice.® For the patients. “
Frasenius Kabi President Region Asia Pacific Oskar Hussonitz said, “This agreement is an important step in intensifying our cooperation and relationship with VFMCRP in nephrology. We believe that velvetasa® It has the potential to provide many benefits to patients across the country, and we look forward to adding it to our portfolio and working with VMMMP. “
Hyperkalemia is a serious medical condition characterized by elevated levels of potassium in the blood and may be associated with life-threatening consequences. Patients with CKD and heart failure, especially those treated with RAAS (renin – angiotensin – aldosterone system) inhibitors, are at particular risk of developing hyperkalemia. As a result, the cornerstone of RAAS therapy, treatment for CKD and heart failure, is often reduced or discontinued, compromising cardio-renal protection. By bringing Veltassa® For China, VFMCRP and Fresenius Kabi will provide a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China, the company ranks among the top 10 multinational pharmaceutical companies, a market leader in clinical nutrition, anesthesia, and nephrology. Fresenius Kabi has about 6,000 employees in China.
Both sides have agreed not to disclose the financial terms of cooperation.
Vifor Pharma Group Is a global pharmaceuticals company. It aims to become a global leader in iron deficiency, nephrology and cardio-renal therapy. The company is the partner of choice for pharmaceuticals and innovative patient-centric solutions. The Vifor Pharma Group strives to help patients around the world with serious and chronic diseases that improve health. The company develops, manufactures and markets pharmaceutical products for precise patient care. Vifor Pharma Group occupies a leading position in all its core business activities and includes the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
for more information please visit viforpharma.com
Fresenius Kabi Is a global healthcare company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to care for critically and chronically ill patients. Fresenius Kabi’s product portfolio includes a wide range of IV generic drugs, infusion treatments and clinical nutrition products, as well as the administration of these products. In the field of biosimilar, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product was launched by Fresenius Kabi. Within transfusion medicine and cell therapy, Fresenius Kabi provides products for the collection of components of blood and for extracorporeal therapy.
With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in people’s hands that help patients and find the best answer to the challenges they face.
for more information please visit www.fresenius-kabi.com.
Approximately (3% of advanced chronic kidney disease (CKD) and 70% of chronic heart failure patients may be at increased risk of increased potassium levels in blood4. Hyperkalemia can cause abnormal heart rhythms and even sudden death5. There are often no warning signs, meaning that a person may inadvertently experience a steady increase in potassium levels and be at risk for these cardiovascular events. Some medications that are often prescribed to people with CKD and heart failure to delay their underlying disease progression and reduce mortality can lead to side effects. These may include angiotensin receptor blockers (ARBs), aldosterone antagonists (AA) and angiotensin converting-enzyme (ACE) inhibitors as well as angiotensin receptor / naprilacine inhibitors (ARNIs) such as RAASIs.
in hell® There is a potassium binder that is approved for the treatment of hyperkalemia. Veltassa® was specifically designed to exchange calcium instead of sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium. Formed in powder form, Veltasai® is mixed with water and taken with or without food once a day. Veltassa® consists of a smooth, spherical, uniform microbead that is too large to absorb, thus protecting the gastrointestinal tract. Veltassa® works primarily in the lumen of the colon where the potassium concentration is the highest, and the polymer has the longest residence time. Potassium is then taken out of the body through a normal excretion process.
1 in hell® European Union SmPC 2019
2 Aggarwal R, et al. Lancet 2019; 394: 1540–50.
3 Zhang et al. Lancet. 2012 March 3; 379 (9818): 815–22; Guo et al. Int J Encutures Res Public Health 2016; 13: E770. Guo et al. Cure Cardiol Rev. 2013 May; 9 (2): 112–122.
4 Rosano GCM, et al. Expert consent document on the management of hyperkalemia in heart disease patients treated with renin angiotensin aldosterone system inhibitors: coordinated by the European Society of Cardiology’s Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2018; 4: 180–188.
5 Rustgar A, Solimani M. Hypokalemia and hyperkalemia. Postgrad Med J. 2001; 77: 759–764.
The content is by Business Wire India. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.